# A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

> **NCT04136444** · PHASE1 · TERMINATED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 12 (actual)

## Conditions studied

- Healthy Study Participants
- Impaired Hepatic Function

## Interventions

- **DRUG:** Padsevonil

## Key facts

- **NCT ID:** NCT04136444
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-28
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-05-22
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136444, "A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04136444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*